首页/数据集/Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

NIAID Data Ecosystem2026-03-14 收录

前列腺癌免疫治疗

CAR-T细胞疗法

数据链接：

https://www.ncbi.nlm.nih.gov/bioproject/PRJNA885901 数据链接链接失效反馈

官方服务：

资源简介：

This SuperSeries is composed of the SubSeries listed below. Overall design: Refer to individual Series

应用场景：

创建时间：

2022-09-30

CAR-T细胞疗法

免疫信号通路

RNAseq analysis of human CAR-Tregs, bearing CD28 or 4-1BB as a costimulatory domains, initially isolated (before engineering) from peripheral blood of healthy donors Overall design: CD25+ naive Tregs

NIAID Data Ecosystem100

Potent stimulation of the androgen receptor instigates a viral mimicry response in prostate cancer [RNA-seq]

前列腺癌免疫治疗

反应模拟

Inhibiting the androgen receptor (AR), a ligand-activated transcription factor, with androgen deprivation therapy is a standard-of-care treatment for metastatic prostate cancer (PCa). Paradoxically, a

NIAID Data Ecosystem30

Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors

CAR-T细胞疗法

药物血液毒性

Cytopenia is one of the most common adverse events following the CAR-T cell infusion, affecting the quality of life and potentially leading to life-threatening bleeding and infection. This study aimed

Taylor & Francis Group2025-09-08 更新20

DataSheet_3_Cyto-IL-15 synergizes with the STING agonist ADU-S100 to eliminate prostate tumors and confer durable immunity in mouse models.xlsx

前列腺癌免疫治疗

小鼠疾病模型

IntroductionProstate cancer is one of the most commonly diagnosed malignancies in men with high mortality rates. Despite the recent therapeutic advances, such as immunotherapies, survival of patients

NIAID Data Ecosystem40

Differential gene expression analysis to investigate prostate tumor responses to intratumoral immunotherapies.

前列腺癌免疫治疗

差异基因表达分析

Purpose: Next-generation sequencing (NGS)-derived transcriptome profiling (RNA-seq) is a powerful tool for analysing cellular pathways involved in treatment responses. In this study, RNA-seq was used

NIAID Data Ecosystem20

Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy. Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy

资源简介：

相关数据集